Cardiac troponin assays: Guide to understanding analytical characteristics and their impact on clinical care

Clinical Chemistry

Volumn 63, Issue 1, 2017, Pages 73-81

  Apple, Fred S ^a   Sandoval, Yader ^b   Jaffe, Allan S ^c   Ordonez Llanos, Jordi ^d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^c MAYO CLINIC   (United States)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TROPONIN I; TROPONIN T;

ASSAY; CARDIAC TROPONIN ASSAY; CLINICAL TRIAL (TOPIC); DIAGNOSTIC ACCURACY; HUMAN; IMPRECISION; LIMIT OF BLANK; LIMIT OF DETECTION; LIMIT OF QUANTITATION; NONHUMAN; PROTEIN DETERMINATION; REFERENCE VALUE; REVIEW; SEX; STATISTICAL PARAMETERS; ACUTE CORONARY SYNDROME; HEART INFARCTION; REPERFUSION INJURY;

ACUTE CORONARY SYNDROME; HUMANS; MYOCARDIAL INFARCTION; REPERFUSION INJURY; TROPONIN I; TROPONIN T;

EID: 85008500412     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2016.255109     Document Type: Review

References (39)

1. Thygesen K, Alpert JS, Jaffe AS, Simooons ML, Chaitman BR White HD, the writing group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction (Apple FS, Biomarker Subcommittee). Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581-98.
2. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al. National Academy of Clinical Biochemistry practice guidelines: clinical characteristics and utilization of biomarkers in acute coronary syndromes. Clin Chem 2007;53:552-74.
3. Cullen L, Aldous S, Than M, Greenslade JH, Tate JR, George PM, et al. Comparison of high sensitivity troponin T and I assays in the diagnosis of non-ST elevation acute myocardial infarction in emergency patients with chest pain. Clin Biochem 2014;47:321-6.
4. Than M, Cullen L, Aldous S, Parsonage WA, Reid CM, Greenslade J, et al. 2-hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker. J Am Coll Cardiol 2012;59:2091-8.
5. Mueller C, Giannitsis E, Christ M, Ordóñez-Llanos J, de-Filippi C, McCord J, et al. Multicenter evaluation of a 0-hour/1-hour algorithm in the diagnosis of myocardial infarction with high-sensitivity cardiac troponin T. Ann Emerg Med 2015;15:1501-2.
6. Than MP, Pickering JW, Aldous SJ, Cullen L, Frampton CM, Peacock WF, et al. Effectiveness of EDACS versus ADAPT accelerated diagnostic pathways for chest pain: a pragmatic randomized controlled trial embedded within practice. Ann Emerg Med 2016;68:93-102.
7. Shah ASV, Anand A, Sandoval Y, Lee KK, Smith SW, Adamson PD, et al, on behalf of the High-STEACS investigators. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort. Lancet 2015;386:2481-8.
8. Apple FS, Steffen LM, Pearce LA, Murakami MM, Luepker RV. Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota Heart Survey. Clin Chem 2012;58:930-5.
9. Sandoval Y, Apple FS. The global need to define normality: the 99th percentile value of cardiac troponin. Clin Chem 2014;60:455-62.
10. Saenger AK, Jaffe AS. Requiem for a heavyweight: the demise of creatine kinase-MB. Circulation 2008;118:2200-6.
11. Jaffe AS, Vasile VC, Milone M, Saenger AK, Olson KN, Apple FS. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol 2011;58:1819-24.
12. Wens SC, Schaaf GJ, Michels M, Kruijshaar ME, van Gestel T, Groen S, et al. Elevated plasma cardiac troponin T levels caused by skeletal muscle damage in Pompe disease. Circ Cardiovasc Genet 2016;9:6-13.
13. Apple FS. Standardization of cardiac troponin I assays will not occur in my lifetime. Clin Chem 2012;58:169-71.
14. Apple FS, Hollander J, Wu AHB, Jaffe AS. Improving the 510k FDA process for cardiac troponin assays: in search of common ground. Clin Chem; 2014;60:1273-5.
15. Apple FS, Collinson PO, for the IFCC Task Force on Clinical Applications of Cardiac Bio-Markers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54-61.
16. Love SA, McKinney ZJ, Sandoval Y, Smith SW, Kohler R, Murakami MM, Apple FS. Electronic health recordbased performance improvement project to document and reduce excessive cardiac troponin testing. Clin Chem 2015;61:498-504.
17. Apple FS. Jaffe AS. Clinical implications of a recent adjustment to the high sensitivity cardiac troponin T assay: user beware. Clin Chem 2012;58:1599-600.
18. Tate JR, Bunk DM, Christenson RH, Barth JH, Katrukha A, Noble JE, et al. Evaluation of standardization capability of current cardiac troponin I assays by a correlation study: results of an IFCC pilot project. Clin Chem Lab Med 2015;53:677-90.
19. Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 2008;29(Suppl 1):S49-52.
20. Apple FS. Opinion. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem 2009;55:1303-6.
21. Apple FS, Jaffe AS, Collinson P, Mockel M, Ordonez-Llanos J, Lindahl B, et al., IFCC Task Force on Clinical Applications of Cardiac Bio-Markers. IFCC educational materials on selected analytical and clinical applications of high-sensitivity cardiac troponin assays. Clin Biochem 2015:2015;48:201-3.
22. Sandoval Y, Smith SW, Schulz KM, Murakami MM, Love SA, Nicholson J, Apple FS. Diagnosis of type 1 and type 2 myocardial infarction using a high-sensitivity cardiac troponin I assay with gender-specific 99th percentiles based on the Third Universal Definition of Myocardial Infarction Classification System. Clin Chem 2015;61:657-63.
23. Rubini Giménez M, Hoeller R, Reichlin T, Zellweger C, Twerenbold R, Reiter M. Rapid rule out of acute myocardial infarction using undetectable levels of highsensitivity cardiac troponins. Int J Cardiol 2013;168:3896-901.
24. Amundson BE, Apple FS. Cardiac troponin assays: a review of quantitative point-of-care devices and their efficacy in the diagnosis of myocardial infarction. Clin Chem Lab Med 2015;53:665-76.
25. Shah A, Griffiths M, Lee KK, McAllister MA, Hunter AL, Cruikshank A, et al. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women. BMJ 2015;350:g7873.
26. Hammerer-Lercher A, Suvisaari J, Apple FS, Christenson RC, Pulkki K, van Dieijeb-Visser P, et al. Howwell do laboratories adhere to recommended clinical guidelines for the management of myocardial infarction: the CARdiac Marker Guidelines Uptake in Europe study (CARMAGUE). Clin Chem 2016;62:1264-71.
27. Collinson PO, Hwung YM, Gaze D, Boa F, Senior R, Christenson R, Apple FS. Influence of population selection on the 99th percentile reference value for cardiac troponin assays. Clin Chem 2012;58:219-25.
28. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012;58:1574-81.
29. Gore MO, Seliger SL, deFilippi CR, Nambi V, Christenson RH, Hashim IA, et al. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol 2014;63:1441-8.
30. Januzzi JL Jr., Bamberg F, Lee H, Truong QA, Nichols JH, Karakas M, et al. High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation 2010;121:1227-34.
31. Bandstein N, Ljung R, Johansson M, Holzmann MJ. Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction. J Am Coll Cardiol 2014;63:2569-78.
32. Eggers KM, Apple FS, Lind L, Lindahl B. The applied statistical approach highly influences the 99th percentile of cardiac troponin I. Clin Biochem 2016;49:1109-12.
33. Apple FS, Smith SW, Pearce LA, Murakami MM. Delta changes for optimizing clinical specificity and 60-day risk of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome utilizing the ADVIA Centaur TnI-Ultra assay. Clin Biochem 2012;45:711-3.
34. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33:2252-7.
35. Jaffe AS, Moeckel M, Giannitsis E, Huber K, Mair J, Mueller C, et al. In search for the Holy Grail: suggestions for the studies to define delta changes to diagnosis or exclude acute myocardial infarction: a position paper from the study group on biomarkers of the Acute Cardiovascular Cares Association. Eur Heart J Acute Cardiovasc Care 2014;4:313-6.
36. Kavsak P, Beattie J, Pickersgill R, Ford, Caruso, Clark L. A practical approach for the validation and clinical implementation of a high-sensitivity cardiac troponin assay across a North American city. Prac Lab Med 2015;1:28-34.
37. Sandoval Y, Smith SW, Apple FS. Present and future of cardiac troponin clinical practice: a paradigm shift to high-sensitivity assays. Am J Med 2016;4:354-65.
38. Love S, Sandoval Y, Apple FS. Incorporating high sensitivity cardiac troponin assays into clinical practice: these assays are your friend. Heart Metab 2015;67:9-14.
39. Love SA, Sandoval Y, Smith SW, Nicholson J, Cao J, Ler R, Schulz K, Apple FS. Incidence of undetectable. Measureable, and increased cardiac troponin I concentrations above the 99th percentile using a high-sensitivity vs a contemporary assay in patients presenting to the emergency department. Clin Chem 2016;62:1115-9.